Abstract
The long-term 'legacy' benefits of statin therapy may extend beyond a reduction in the risk of cardiovascular events to include protection against infection and respiratory disease. The Anglo–Scandinavian Cardiac Outcomes Trial (ASCOT) investigators have drawn this conclusion on the basis of 11-year follow-up data from British patients enrolled in the lipid-lowering arm of their multicenter, randomized trial. The latest results from this study were reported at the European Society of Cardiology 2011 Congress and published in the European Heart Journal.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
